Transgene Biotek

Transgene Biotek Gross Margin

The Gross Margin of Transgene Biotek (526139.BO) as of Nov 3, 2026 is 100.00 %. In the previous year, Gross Margin was 100.00 % — a change of 0.00% (lower).

Gross Margin

100.00 %

YoY

0.00%

Last updated:

Gross Margin of Transgene Biotek is 2026 100.00 % . Gross Margin of Transgene Biotek was 2025 100.00 % . It decreases by 0.00% lower compared to the previous year.

For Transgene Biotek, the gross margin of 100.0% is down versus 153.3% a few years ago.

The Transgene Biotek Gross Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Margin
Date
Gross Margin
Jan 1, 2019
52.51 INR
Jan 1, 2020
-313.59 INR
Jan 1, 2021
64.12 INR
Jan 1, 2022
153.31 INR
Jan 1, 2023
-20.33 INR
Jan 1, 2024
99.74 INR
Jan 1, 2025
100.00 INR
Jan 1, 2026
100.00 INR
The Transgene Biotek Gross Margin history
YEARGross MarginYoY
100.00 %0.00%
100.00 %+0.26%
99.74 %-590.71%
-20.33 %-113.26%
153.31 %+139.08%
64.12 %-120.45%
-313.59 %-697.18%
52.51 %-47.27%
99.59 %+4.04%
95.72 %+26.77%
75.51 %+180,045.76%
0.04 %-72.83%
0.15 %-62.57%
0.41 %-48.41%
0.80 %-7.04%
0.86 %+4.03%
0.83 %-0.66%
0.83 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Transgene Biotek Stock analysis

What does Transgene Biotek do? Transgene Biotek Ltd. generates revenue through the sale of diagnostic kits and its portfolio of products, including oncology, auto-immunity, drug delivery, and biogenerics solutions. The company offers TrabiAAV, a platform for delivering miRNAs, ShRNAs, and immunogens in gene therapy, and TrabiORAL, which enables oral delivery of proteins and peptides for treating human diseases. Its TBL-1203 product strengthens cell-mediated immunity to eliminate HIV without retroviral therapy, while Tacrolimus suppresses the immune system to prevent organ transplant rejection. These products are targeted at healthcare providers, research institutions, and pharmaceutical companies seeking advanced therapeutic solutions. The firm’s R&D focus on vaccines, oncology, and new drug delivery technologies supports its product development pipeline. TrabiAAV and TrabiORAL are positioned as innovative delivery platforms, while TBL-1203 and Tacrolimus address specific medical needs in HIV treatment and transplant medicine. The company’s diagnostic kits cater to clinical laboratories and hospitals requiring reliable testing solutions for oncology and autoimmune conditions. Transgene Biotek Ltd. serves healthcare professionals, pharmaceutical firms, and research organizations through its specialized products. Its oncology and auto-immunity kits are used in diagnostic settings, while its therapeutic platforms like TrabiAAV and TrabiORAL support drug development for complex diseases. The company’s focus on biogenerics and novel delivery systems aligns with market demands for cost-effective and targeted therapies. Transgene Biotek is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Transgene Biotek stock

Gross Margin of Transgene Biotek is 100.00 % in 2026.

Gross Margin of Transgene Biotek changed from 100.00 % to 100.00 %, representing a 0.00% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Gross Margin Transgene Biotek since 2006 – with annual values, charts, and detailed analysis.

Gross Margin measures the percentage of revenue remaining after COGS. Higher gross margins indicate more efficient production and stronger pricing power.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Gross Margin's Transgene Biotek with sector peers and the industry average to assess whether it is attractive.

To evaluate Gross Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Gross Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Margins — Transgene Biotek

Gross MarginEBIT MarginEBITDA MarginNet MarginFCF MarginR&D / RevenueTax RatePayout RatioPre-Tax MarginOCF MarginSGA/RevenueOpEx/RevenueReinvestment Rate

All Key Metrics — Transgene Biotek